3Billion Inc is a Korea-based company principally engaged in the provision of genetic testing services. The Company is principally engaged in the provision of rare genetic disease diagnostic testing services. The Company is also engaged in the research and development of technology that automatically reads the pathogenicity of numerous genetic variants found in the genome.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
23/09/26	₩5,800.00	+23.27%	3,785,681
22/09/26	₩4,705.00	0.00%	386,634
21/09/26	₩4,705.00	-1.36%	365,088
18/09/26	₩4,770.00	+10.67%	1,118,000
17/09/26	₩4,310.00	+6.16%	883,981

End-of-day quote Korea S.E.

More quotes

Annual profits - Rate of surprise

Company calendar

End-of-day quote Korea S.E. 23/09/2026			5-day change	1st Jan Change
5,800.00 ^KRW	+23.27%		+42.86%	-68.18%

06-01	3billion Launches 3B-NEO, Genomic Newborn Screening Service Covering 595 Clinically Actionable Genetic Conditions	CI
05-12	3billion, Inc. announced that it has received KRW 29.9999999 billion in funding from Meritz Securities Co., Ltd., Wonik Investment Partners Co., Ltd.	CI

Market Cap	185B 135M 119M 111M 102M 190M 12.94B 192M 1.34B 519M 6.6B 507M 496M 21.4B	P/E 2025	-107x	P/E 2026 *	-
Enterprise Value	168M 123K 108K 101K 92.6K 173K 11.76M 174K 1.22M 472K 6M 461K 451K 19.44M	EV / Sales 2025	49x	EV / Sales 2026 *	-
Free-Float	75.33%	Yield 2025 *	-	Yield 2026 *	-

06-01	3billion Launches 3B-NEO, Genomic Newborn Screening Service Covering 595 Clinically Actionable Genetic Conditions	CI
05-12	3billion, Inc. announced that it has received KRW 29.9999999 billion in funding from Meritz Securities Co., Ltd., Wonik Investment Partners Co., Ltd.	CI
04-22	3billion, Inc. announced that it expects to receive KRW 29.999999888 billion in funding from Meritz Securities Co., Ltd., Wonik Investment Partners Co., Ltd. and other investors.	CI
04-09	3Billion Inc wins 955 million won order	RE
03-23	3billion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
18/03/25	3Billion Inc Wins 655 Million Won Order	RE

1 day	+23.27%
1 week	+42.86%
Current month	+11.97%
1 month	+7.01%
3 months	-3.49%
6 months	-54.93%
Current year	-68.18%

3billion, Inc. Share Price

Stocks

A394800

KR7394800007

Biotechnology & Medical Research

Valuation: 3billion, Inc.

Chart: 3billion, Inc.

Latest news: 3billion, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: 3billion, Inc.

Latest insider transactions

Bio Diagnostics & Testing

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

1 week	4,575	6,100
1 month	4,020	6,100
Current year	4,020	18,690
1 year	4,020	20,100
3 years	3,025	20,100
5 years	3,025	20,100
10 years	3,025	20,100

Manager	Title	Age	Since
Chang-Won Geum CEO	Chief Executive Officer	45	09/10/2016
Soon-Il Park DFI	Director of Finance/CFO	46	30/09/2020
Jeong-Seol Lee CTO	Chief Tech/Sci/R&D Officer	46	31/07/2018

Director	Title	Age	Since
Chang-Won Geum BRD	Director/Board Member	45	09/10/2016
Se-Hwan Kim BRD	Director/Board Member	44	09/10/2016
Ki-Hyeon Kang BRD	Director/Board Member	44	17/11/2020

Date	Insider	Type	Main position	Quantity	% Market Cap.
16/04/25	Soon-Il Park	Others	Chief Financial Officer	44,000	0.1387%
07/03/25	Soon-Il Park	Exercice	Chief Financial Officer	40,000	0.1262%
07/03/25	Ki-hyun Kang	Exercice		10,000	0.0316%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
3BILLION, INC.	+23.27%	+42.86%	-22.56%	-	135M
IOVANCE BIOTHERAPEUTICS, INC.	+1.47%	+1.83%	+381.27%	+123.26%	4.62B
ADAPTIVE BIOTECHNOLOGIES CORPORATION	+2.13%	-0.09%	+122.50%	+461.52%	4.45B
VERACYTE, INC.	+3.95%	+12.62%	+39.81%	+103.34%	3.52B
CAREDX, INC.	+9.10%	+9.14%	+293.16%	+675.00%	2.81B
BGI GENOMICS CO., LTD.	+2.50%	+22.28%	-7.77%	-15.52%	2.52B
FREENOME, INC.	+0.70%	+6.59%	+48.11%	-	1.69B
SEEGENE, INC.	-0.58%	+4.78%	+29.52%	+61.14%	1.13B
MARAVAI LIFESCIENCES HOLDINGS, INC.	-0.47%	+1.03%	+170.04%	-21.02%	1.1B
CURIOX BIOSYSTEMS CO., LTD	+5.08%	+4.75%	-20.77%	+84.39%	625M
Average	+4.72%	+7.65%	+103.33%	+184.01%	2.26B
Weighted average by Cap.	+3.03%	+5.14%	+156.44%	+237.97%

	2025	2026 *
Net sales	10.8B 7.91M 6.94M 6.52M 5.96M 11.15M 757M 11.23M 78.36M 30.38M 386M 29.69M 29.04M 1.25B	-
Net income	-5.8B -4.25M -3.73M -3.5M -3.2M -5.99M -407M -6.03M -42.08M -16.31M -207M -15.95M -15.6M -672M	-
Net Debt	-16.9B -12.37M -10.86M -10.21M -9.33M -17.44M -1.19B -17.57M -123M -47.54M -604M -46.47M -45.45M -1.96B	-